Eligard HCP Template Site

Menu

 DISCOVER THE DEPTH OF ELIGARD’S EVIDENCE

Proven long-term

efficacy and tolerability

Over 20 years

of clinical use worldwide1-6

Asset 7

PROFOUND
SUPPRESSION2

Read More
Asset 8

PROVEN LONG-TERM
EFFICACY1

Read More
Asset 9

NO KNOWN DRUG
INTERACTIONS4-6

Read More
Asset 10

DECADES OF
EXPERIENCE1-6

Read More

Maintaining testosterone levels
with ELIGARD 1, 3, 6 month doses2,7   

ELIGARD profoundly suppresses testosterone
To levels associated with improved outcomes*2,7

ELIGARD 1-month achieved
profound suppression of
testosterone
(≤20 ng/dL)
in 97.5% of patients4

ELIGARD 3-month achieved
profound suppression of
testosterone
(≤20 ng/dL)
in 94% of patients5

ELIGARD 6-month achieved
profound suppression of
testosterone
(≤20 ng/dL)
in 88% of patients6

ELIGARD 1-month achieved profound suppression of testosterone (≤20 ng/dL) in 97.5% of patients4

1 Month Graph

ELIGARD 3-month achieved profound suppression of testosterone (≤20 ng/dL) in 94% of patients5

3 Month Graph

ELIGARD 6-month achieved profound suppression of testosterone (≤20 ng/dL) in 88% of patients6

6 Month Graph

ELIGARD maintains testosterone levels of
≤20 ng/dL with fewer than
1% of breakthroughs1,4–6,8

*The EAU-recommended testosterone level is <20 ng/dL.7 This definition is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL.2 EAU, European Association of Urology; NCCN, National Comprehensive Cancer Network; SEM, standard error of mean.

See ELIGARD’s long-term
testosterone control 

ELIGARD offers proven efficacy, year after year
For reassurance in long-term control

ELIGARD has consistently demonstrated durable and reliable long-term
testosterone suppression4–6 a critical factor in the effective management
of advanced prostate cancer

With continuous administration of 6-monthly injections ELIGARD achieved:

 At 6 months

10.4

ng/dL

(±0.53 ng/dL)

average testosterone level1,6

97%

reduction
in PSA levels1,6

 At 12 months

96%

of patients

had normalised
PSA levels6

ELIGARD has been proven in clinical trials to maintain profound testosterone suppression to surgical castration levels* for up to 7 years (and presumably indefinitely),†1 potentially extending time to disease progression and improving patient survival9

*The EAU-recommended testosterone level is <20 ng/dL.7 This definition is important as better results are repeatedly observed with lower testosterone levels compared to 50 ng/dL.2

†Shown in long-term studies.

EAU, European Association of Urology; PSA, prostate-specific antigen.

ELIGARD is well-tolerated

With an established safety profile

Discover ELIGARD’s
saftey and tolerability

Most of the AEs
reported in clinical
trials were
mild-to-moderate4–6
No known drug interactions with ELIGARD which simplifies integration into treatment regimens*1,10
No treatment discontinuations due to treatment-related AEs, in clinical studies4–6
Localised injection reactions are generally mild and transient when administered correctly1

With ELIGARD, you can confidently prescribe an ADT

which demonstrates the lowest risk of cardiovascular toxicity among LHRH agonists and GnRH antagonists11,12

*Concomitant use of ELIGARD with medicines causing a lengthening of the QT interval or capable of inducing Torsades de pointes must be carefully evaluated.1

ADT, androgen deprivation therapy; AE, adverse event; GnRH, gonadotropin releasing hormone; LHRH, luteinising hormone-releasing hormone.

ELIGARD has over
20 years of clinical use
demonstrating its
efficacy and safety1–6

Proven efficacy and safety
data from over 20 published
clinical trials and real-world
experience1–6

Proven to suppress
testosterone in clinical
studies independent of
age and body weight13

See how ELIGARD’s
administration works

References

  1. ELIGARD SmPC. Latest version.
  2. Shore ND, et al. BJU Int. 2017;119:239–244.
  3. Tolmar. PSUR. 2023. Data on File.
  4. Perez-Marrero R, et al. Clin Ther. 2002;24:1902–1914.
  5. Chu FM, et al. J Urol. 2002;168:1199–1203.
  6. Crawford ED, et al. J Urol. 2006; 175: 533–536.
  7. Cornford P, et al. EAU Guidelines. Edn. presented at EAU Paris April 2024. ISBN 978-94-92671-23-3.
  1. Tombal B, et al. Eur Urol Suppl. 2007;6:754–760.
  2. Crawford ED, et al. Prostate Cancer Prostatic Dis. 2019;22(1):24–38.
  3. Ruplin A, et al. J Oncol Pharm Pract. 2024;30(6):1057–1072.
  4. Lyon AR, et al. Eur Heart J. 2022;43:4229–4361.
  5. Alekseev BYa et al. Cancer Urology. 2024;20(3):80–93.
  6. Renzulli JF, et al. BJUI Compass. 2020;1:64–73.

This website is intended for healthcare professionals only.

 

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent
advanced prostate cancer and for the treatment of high-risk localised and locally
advanced hormone dependent prostate cancer in combination with radiotherapy.1

GL-ELIGA-0020 | July 2025 © 2025 Recordati